US › Healthcare

Coherus BioSciences Inc (CHRS)

US · Healthcare · Biotechnology

$1.23+0.82%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$14.3M

Revenue YoY

+39.5%

Net profit

$-20.6M

EPS

$-0.22

EPS estimate

$-0.16

Net margin

-144.2%

EPS came in at -0.22 against a street estimate of -0.16 — a miss of 37.5%.

Key statistics

Market cap

$207.0M

Forward P/E

41.2

P/B

3.35

Book value

$0.39

EPS (TTM)

$-1.26

52-week high

$2.62

52-week low

$1.09

50-day MA

$1.40

200-day MA

$1.57

Beta

0.94

Analyst view

Analysts rate Coherus BioSciences Inc a buy (4 buy, 3 hold, 0 sell out of 7) with an average price target of $7.75.

Shareholding

Insiders

19.12%

Institutions

37.41%

Largest institutional holders

Fund	Stake
BlackRock Inc	6.71%
Vanguard Capital Management, LLC	3.53%
Samsara BioCapital, LLC	2.22%
Geode Capital Management, LLC	2.02%
Kohlberg Kravis Roberts & Co LP	1.97%
State Street Corp	1.51%
Two Sigma Investments LLC	1.49%
Alyeska Investment Group, L.P.	1.46%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Coherus BioSciences Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.